[{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PIPE-505","moa":"Gamma-secretase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Contineum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Contineum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Franklin Templeton","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Other Small Molecule","year":"2021","type":"Series C Financing","leadProduct":"PIPE-505","moa":"Gamma-secretase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Contineum Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0.080000000000000002,"dosageForm":"Intratympanic Injection","sponsorNew":"Contineum Therapeutics \/ Franklin Templeton","highestDevelopmentStatusID":"7","companyTruncated":"Contineum Therapeutics \/ Franklin Templeton"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PIPE-505","moa":"Gamma-secretase","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intratympanic Injection","sponsorNew":"Contineum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Contineum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"PIPE-307","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Contineum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Contineum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"PIPE-307","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Contineum Therapeutics","amount2":1.1000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":1.1000000000000001,"dosageForm":"Intravenous Injection","sponsorNew":"Contineum Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Contineum Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PIPE-307","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Contineum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Contineum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PIPE-307","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Contineum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Contineum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"PIPE-307","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Contineum Therapeutics","amount2":0.11,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.11,"dosageForm":"Oral Tablet","sponsorNew":"Contineum Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"Contineum Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Jeffrey C. Thacker","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"PIPE-307","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Contineum Therapeutics \/ Jeffrey C. Thacker","highestDevelopmentStatusID":"8","companyTruncated":"Contineum Therapeutics \/ Jeffrey C. Thacker"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"PIPE-307","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Contineum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Contineum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PIPE-791","moa":"LPA1","graph1":"Neurology","graph2":"Phase I","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Contineum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Contineum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PIPE-791","moa":"LPA1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Contineum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Contineum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PIPE-791","moa":"LPA1","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Contineum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Contineum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PIPE-791","moa":"LPA1","graph1":"Neurology","graph2":"Phase I","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Contineum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Contineum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PIPE-791","moa":"LPA1","graph1":"Neurology","graph2":"Phase I","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Contineum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Contineum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PIPE-307","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Contineum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Contineum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PIPE-307","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Contineum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Contineum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"PIPE-307","moa":"M1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Contineum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Contineum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PIPE-791","moa":"LPA1","graph1":"Neurology","graph2":"IND Enabling","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Contineum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Contineum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PIPE-791","moa":"LPA1","graph1":"Neurology","graph2":"Phase I","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Contineum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Contineum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PIPE-791","moa":"LPA1","graph1":"Neurology","graph2":"Phase I","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Contineum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Contineum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PIPE-791","moa":"LPA1","graph1":"Neurology","graph2":"Phase I","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Contineum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Contineum Therapeutics \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Contineum Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CAMX
                          Not Confirmed
                          CAMX
                          Not Confirmed

                          Details : PIPE-791 is a novel, brain penetrant, small molecule antagonist of the LPA1R, being investigated for the treatment of chronic pain associated with osteoarthritis and low back pain.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 04, 2025

                          Lead Product(s) : PIPE-791

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          CAMX
                          Not Confirmed
                          CAMX
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 05, 2025

                          Lead Product(s) : PIPE-791

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          CAMX
                          Not Confirmed
                          CAMX
                          Not Confirmed

                          Details : PIPE-307 is a potentially first-in-class M1 receptor antagonist in development for patients with relapsing-remitting multiple sclerosis (RRMS).

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 08, 2025

                          Lead Product(s) : PIPE-307

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          CAMX
                          Not Confirmed
                          CAMX
                          Not Confirmed

                          Details : PIPE-791 is a novel, brain penetrant, small molecule antagonist of the LPA1R, being investigated for the treatment of chronic pain associated with osteoarthritis and low back pain.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 18, 2024

                          Lead Product(s) : PIPE-791

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          CAMX
                          Not Confirmed
                          CAMX
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 12, 2024

                          Lead Product(s) : PIPE-791

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          CAMX
                          Not Confirmed
                          CAMX
                          Not Confirmed

                          Details : Proceeds will support the clinical development of PIPE-307, a small molecule G1 receptor inhibitor, in phase II trials for relapsing-remitting multiple sclerosis.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          April 04, 2024

                          Lead Product(s) : PIPE-307

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Goldman Sachs & Co

                          Deal Size : $110.0 million

                          Deal Type : Public Offering

                          blank

                          07

                          CAMX
                          Not Confirmed
                          CAMX
                          Not Confirmed

                          Details : Proceeds will fund the clinical development of PIPE-307, a G1 receptor inhibitor in phase II trials for relapsing-remitting multiple sclerosis.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 15, 2024

                          Lead Product(s) : PIPE-307

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Jeffrey C. Thacker

                          Deal Size : Undisclosed

                          Deal Type : Public Offering

                          blank

                          08

                          CAMX
                          Not Confirmed
                          CAMX
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 16, 2023

                          Lead Product(s) : PIPE-307

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          CAMX
                          Not Confirmed
                          CAMX
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 09, 2023

                          Lead Product(s) : PIPE-791

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          CAMX
                          Not Confirmed
                          CAMX
                          Not Confirmed

                          Details : PIPE-791 is a potent, selective, brain-penetrant small molecule antagonist of the LPA1 receptor that has demonstrated activity in in vitro and in vivo models and was tolerated in IND-enabling studies for Multiple sclerosis.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 06, 2023

                          Lead Product(s) : PIPE-791

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank